Ceftazidime-Avibactam is Superior to Tigecycline for Carbapenem-Resistant Enterobacterales Intra-Abdominal Infections
For carbapenem-resistant Enterobacterales (CRE) intra-abdominal infections, ceftazidime-avibactam should be the preferred agent over tigecycline, with the specific regimen determined by the carbapenemase type.
Treatment Algorithm Based on Carbapenemase Type
For KPC-Producing CRE (Most Common in Many Regions)
- Use ceftazidime-avibactam monotherapy as first-line treatment 1, 2
- This is the most straightforward scenario with robust guideline support
For NDM-Producing CRE (Metallo-β-lactamase)
- Preferred: Aztreonam-avibactam (if available) 1
- Alternative: Ceftazidime-avibactam PLUS aztreonam (when aztreonam-avibactam unavailable) 1, 2
- This combination is necessary because ceftazidime-avibactam alone is ineffective against metallo-β-lactamases
- The combination showed 81% 30-day survival versus 56% with polymyxin/tigecycline-based therapy in bloodstream infections 1
For OXA-48-Like Producers
- Use ceftazidime-avibactam (effective against this carbapenemase type) 1
Why Ceftazidime-Avibactam Over Tigecycline
The evidence strongly favors ceftazidime-avibactam:
Clinical Efficacy Data:
- Tigecycline FDA trials for complicated intra-abdominal infections showed clinical cure rates of 80.6-91.3% against susceptible organisms 3
- However, these trials compared tigecycline to imipenem/cilastatin in non-resistant Enterobacterales
- Critical limitation: Tigecycline has no specific FDA indication or robust trial data for carbapenem-resistant organisms in intra-abdominal infections 3
Comparative Evidence:
- In critically ill patients with carbapenem-resistant Klebsiella pneumoniae, ceftazidime-avibactam achieved superior clinical cure (51.2% vs 29.0%, P=0.022) and microbiological cure (74.4% vs 33.9%, P<0.001) compared to tigecycline 4
- Meta-analysis of tigecycline for CRE showed no mortality benefit over other agents, with combination therapy performing better than monotherapy 5
- Ceftazidime-avibactam demonstrated comparable efficacy to carbapenems in complicated intra-abdominal infections, with 91% clinical cure rates 6
Critical Pitfalls to Avoid
Do NOT use ceftazidime-avibactam alone for NDM-producers - it will fail. You must add aztreonam or use aztreonam-avibactam 1, 2
Obtain rapid carbapenemase testing - treatment selection depends critically on the carbapenemase type. Molecular diagnostics should guide therapy within 24-48 hours 1, 2
Monitor for transaminase elevations when using ceftazidime-avibactam plus aztreonam - occurred in 40% of healthy volunteers at high aztreonam doses, though typically asymptomatic and reversible 1
Avoid tigecycline monotherapy - if tigecycline must be used (due to unavailability of preferred agents), use combination therapy as monotherapy showed inferior outcomes 5
When Tigecycline Might Be Considered
Tigecycline should be relegated to a last-resort option only when:
- Ceftazidime-avibactam is unavailable
- The patient has documented susceptibility to tigecycline (MIC ≤2 mg/L)
- It is used in combination with other active agents (never as monotherapy) 1, 5
- The patient has hepatic function adequate to tolerate tigecycline
The 2026 IDSA guidelines explicitly recommend ceftazidime-avibactam (with or without aztreonam depending on carbapenemase type) as preferred therapy, with polymyxin- or tigecycline-based regimens showing significantly worse outcomes (56% vs 81% 30-day survival for NDM-producers) 1.
The mortality and morbidity data clearly favor ceftazidime-avibactam-based regimens over tigecycline for carbapenem-resistant Enterobacterales intra-abdominal infections.